Patents by Inventor Nuzhat Pathan

Nuzhat Pathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Combination Therapy to Treat Cancer
    Publication number: 20210077463
    Abstract: This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of a MEK inhibitor and a PD-1 axis binding antagonist, or a combination of a MEK inhibitor and a PARP inhibitor, or a combination of a MEK inhibitor and a PD-1 axis binding antagonist and a PARP inhibitor to a patient in need thereof.
    Type: Application
    Filed: December 17, 2018
    Publication date: March 18, 2021
    Inventors: Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Nuzhat Pathan, Patrice A. Lee, Shannon L. Winski
  • METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS
    Publication number: 20180370966
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 27, 2018
    Inventors: Kenneth Egnard LIND, Kathy CAO, Edward Yin-shiang LIN, Thinh Ba NGUYEN, Bradley T. TANGONAN, Daniel A. ERLANSON, Kevin GUCKIAN, Robert Lowell SIMMONS, Wen-cherng LEE, Lihong SUN, Stig HANSEN, Nuzhat PATHAN, Lei ZHANG
  • Methods of treatment using pyridinonyl PDK1 inhibitors
    Patent number: 9873693
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: January 23, 2018
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • PYRIDINONYL PDK1 INHIBITORS
    Publication number: 20150018351
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 15, 2015
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • Pyridinonyl PDK1 inhibitors
    Patent number: 8778977
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: July 15, 2014
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • PYRIDINONYL PDK1 INHIBITORS
    Publication number: 20100144730
    Abstract: The present invention provides pyridinonyl PDK1 inhibitors and methods of treating cancer using the same.
    Type: Application
    Filed: July 2, 2007
    Publication date: June 10, 2010
    Applicants: Sunesis Phamaceuticals, Biogen IDEC,INC
    Inventors: Kenneth Egnard Lind, Kathy Cao, Edward Yin-shiang Lin, Thinh Ba Nguyen, Bradley T. Tangonan, Daniel A. Erlanson, Kevin Guckian, Robert Lowell Simmons, Wen-cherng Lee, Lihong Sun, Stig Hansen, Nuzhat Pathan, Lei Zhang
  • USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
    Publication number: 20080213168
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: August 17, 2007
    Publication date: September 4, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
  • USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
    Publication number: 20080213260
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: August 17, 2007
    Publication date: September 4, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
  • USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
    Publication number: 20080213167
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: August 17, 2007
    Publication date: September 4, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
  • USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
    Publication number: 20080171056
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: August 17, 2007
    Publication date: July 17, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
  • Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
    Publication number: 20060286101
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: August 11, 2006
    Publication date: December 21, 2006
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary Braslawsky, Nuzhat Pathan
  • USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
    Publication number: 20060171950
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: March 30, 2006
    Publication date: August 3, 2006
    Applicant: Biogen Idec Inc.
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary Braslawsky, Nuzhat Pathan
  • Use of CD23 antagonists for the treatment of neoplastic disorders
    Publication number: 20030211107
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: September 12, 2002
    Publication date: November 13, 2003
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary R. Braslawsky, Nuzhat Pathan
  • Use of CD23 antagonists for the treatment of neoplastic disorders
    Publication number: 20020159996
    Abstract: Methods and kits for the treatment of neoplastic disorders comprising the use of a CD23 antagonist are provided. The CD23 antagonist may be used alone or in combination with chemotherapeutic agents. In particularly preferred embodiments the CD23 antagonists may be used to treat B cell chronic lymphocytic leukemia (B-CLL).
    Type: Application
    Filed: November 5, 2001
    Publication date: October 31, 2002
    Inventors: Kandasamy Hariharan, Nabil Hanna, Gary Braslawsky, Nuzhat Pathan